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Abstract
Bone morphogenetic proteins (BMPs) are cytokines with a strong effect on bone and cartilage
growth and with important roles during embryonic patterning and early skeletal formation.
BMPs have promising potential for clinical bone and cartilage repair, working as powerful bone-
inducing components in diverse tissue-engineering products. Synthetic polymers, natural origin
polymers, inorganic materials and composites may be used as carriers for the delivery of BMPs.
Carriers range from nanoparticles to complex three-dimensional (3D) scaffolds, membranes for
tissue-guided regeneration, biomimetic surfaces and smart thermosensitive hydrogels. Current
clinical uses include spinal fusion, healing of long bone defects and craniofacial and periodontal
applications, amongst others. BMP-2 and BMP-7 have recently received approval by the US Food
and Drug Administration (FDA) for specific clinical cases, delivered in absorbable collagen sponges.
Considering the expanding number of publications in the field of BMPs, there are prospects of a
brilliant future in the field of regenerative medicine of bone and cartilage with the use of BMPs.
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1. Introduction
Every year millions of surgical operations are performed
for the healing or repair of an organ. In the past
two decades, tissue engineering has emerged as a very
promising alternative that circumvents several of the
limitations of the existing options of autografting and
allografting for the treatment of a malfunction or lost body
part. Tissue engineering combines precursor cells from
the patient with scaffolding matrices and the stimulus of
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growth factors. Since the advent of tissue engineering,
bone has received particular interest, since it is one of the
tissues with most regenerative abilities in the human body.
Bone morphogenetic proteins (BMPs) are probably the
most important growth factors in bone formation and
healing (Reddi, 1998, 2005). These cytokines have been
extensively studied during recent decades and, nowadays,
recombinant human BMPs (rhBMPs) are widely used
in several tissue-engineering products that might serve
for the complete regeneration of bone or cartilage.
Current applications include rhBMPs loaded in delivery
systems made of synthetic or natural polymers and the
differentiation of transplanted stem cells from the patient
with rhBMPs for later body implantation. The purpose
of this review is to cover the latest developments in
the research for a BMP delivery carrier involving the
Copyright  2008 John Wiley & Sons, Ltd.
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use of biomaterials science, particularly with the use of
natural origin polymers, to the recent preclinical trials
and approved products for clinical applications.
2. Delivering BMPs
2.1. BMP carriers – from bench to clinical
approval
The main role of a delivery system for BMPs is to retain
these growth factors at the site of injury for a prolonged
time frame, providing an initial support to which cells
attach and form regenerated tissue (Seeherman and
Wozney, 2005). The carrier should provoke optimal
inflammatory responses, be biodegradable to allow the
formation of an interface with the surrounding biological
tissue or complete biodegradability for complete invasion
of healed tissues, and present adequate porosity to allow
the infiltration of cells and formation of blood vessels at
the new bone. Furthermore, the carrier should protect the
BMPs from degradation and maintain its bioactivity whilst
releasing the protein in a time- and space-controlled way
to promote the formation of new bone at the treatment
site. Finally, carriers should be conveniently sterilizable,
easy to handle, stable over time with well-defined storage
procedures, as well as suitable for commercial production,
allowing scale-up production and approval by regulatory
agencies. The type of tissue to be regenerated is also of
critical importance, as different mechanical requirements
apply for the repair of bone, cartilage or tendon. For
example, bone carriers are simplified by the fact that,
upon fracture, bone is immobilized, but carriers should
allow vascular ingrowth, due to the highly vascularized
nature of bone. In cartilage, defects are subject to high
compressive and shear stresses, thus making healing more
challenging. In tendon, the regenerative ability appears to
be intermediate between those of bone and cartilage, so
tendons are very difficult to immobilize, needing a carrier
that is able to withstand considerable tensile forces.
The geometry of the carrier also significantly affects
the biophysical process of osteoinduction and capillary
penetration (Jin et al., 2000). Taking all these factors
into consideration, researchers also have to keep in mind
that the carrier is evidently aimed for common usage by
surgeons and physicians.
2.2. BMP retention at the orthopaedic site
The delivery of BMP should last for a sufficient period of
time to induce a specific amount of bone mass to treat the
defect. Retention of BMP at the orthopaedic site of injury
is affected by many parameters, such as the interaction
between the biomaterial and the BMP, and the influence
of pH, temperature, porosity and the influence of salt
concentrations. Evidently, retention of the growth factor
depends on whether the BMP is immobilized on the carrier
during its manufacture or absorbed into the surface of the
device.
Immobilization of the BMPs in a delivery system
may be performed by different methodologies: via
adsorption, entrapment or immobilization, or by covalent
binding (Luginbuehl et al., 2004). In case of adsorption,
impregnation of the delivery matrix with the BMP is
simpler but conformational changes might occur and the
release of the protein be less sustained. Furthermore,
delivery by adsorbed growth factors often results in
initial burst release. With entrapment methodology,
hydrophobic polymeric matrices are well known and
described to immobilize and release bioactive agents
over extended periods of time (Langer and Folkman,
1976). However, difficulty arises over the fact that during
processing of certain materials into carriers, pH conditions
or temperature conditions often result in denaturation of
the protein. Much research nowadays aims to develop
specific methods of producing delivery carriers for BMPs
that do not cause their loss of activity. Lastly, the BMP may
become immobilized by covalent binding to the carrier.
This may be performed by production of a fusion BMP
protein with a domain of specific binding to a biomaterial
(Suzuki et al., 2000). In this regard, recombinant
technology offers great versatility for expression of a
BMP capable of binding to most natural polymers.
Other interesting approaches include exploring the strong
affinity of BMPs to the extracellular matrix heparan
sulphate/heparin proteoglycans (Blanquaert et al., 1999),
ion complexation by binding to charged polymers,
as in the cases of chitosan, alginate, hyaluronans or
synthetic polyelectrolytes (Yamamoto et al., 1998), and
crystallization of growth factors (Jen et al., 2002).
2.3. Pharmacokinetic profiles of released BMPs
It is crucial to consider that release should preferably
be sustained over time. Extremes in release profiles,
such as long low-amount release of BMPs or initial
burst of BMPs, are known not to be beneficial to
bone healing. A delicate balance in the concentration
of BMPs helps to prevent either insufficient binding to
the carrier due to low concentration or precipitation due
to high BMP concentration. The time of release may be
dependent on the type of fracture or the application
in question. It is clear that there is more than one
desirable pharmacokinetic profile. The pharmacokinetic
profile varies according to the material in consideration,
its formulation and the type and amount of BMP in
use. By chemical modification of the carrier or the BMP,
we may achieve a specific release profile, which is of
interest since different BMPs may present different release
profiles due to their different amino acid sequences; and
different species have different optimal release profiles
(Li and Wozney, 2001) and the chances are that the
optimal profile may be also site-specific. Depending
on the site of injury or on a particular application,
various formulations of delivery systems may be designed,
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from simple nano/microparticles to scaffolds of increased
three-dimensional (3D) complexity, such as those that
mimic the physical properties of the extracellular matrix,
or hydrogels that respond to physiological shifts such as
pH or temperature.
3. Carrier BMPs
3.1. Synthetic biodegradable polymers
Synthetic polymers have been widely used in tissue-
engineering applications (Saito and Takaoka, 2003) (See
Table 1). Initially, poly(lactic acid) (PLA) was investi-
gated as a carrier for BMP delivery (Miyamoto et al.,
1992) but the material was considered ineffective due
the release of acidic degradation by-products. However,
novel biodegradable synthetic polymers have attracted
attention, since these are free of the risk of disease trans-
mission that occurs with other materials used for bone
applications, such as collagen. Biodegradable polymers,
such as polylactic acid–p-dioxanone–polyethylene glycol
(PLA–DX–PEG), allow percutaneous injection after heat-
ing, for use as a scaffold and a delivery carrier for BMPs,
due to its versatile temperature-dependent liquid–semi-
solid transition. This plasticity allows the biodegradation
of the polymer to be synchronized with the induction
of new bone by BMP (Saito et al., 2001), and this type
of injectable polymeric delivery system, polymerization
in situ, enables a less invasive approach to bone surgery
(Saito et al., 2003b). These scaffolds were tested, as carri-
ers for BMPs, in a variety of models, such as a canine spinal
fusion model and in the formation of artificial joints (Saito
et al., 2005b), for long bone defects in rabbits (Yoneda
et al., 2005) and in dogs (Murakami et al., 2003), and in
healing of rat cranial defects (Suzuki et al., 2006). These
studies showed that PLA–DX–PEG delivered rhBMP-2
successfully, inducing the repair of bone defects several
weeks after implantation. In other reports, composites
of PLA–DX–PEG with calcium phosphate were shown to
require less rhBMP to induce new bone formation in mice
(Matsushita et al., 2004) and in healing femur defects of
rabbits (Matsushita et al., 2006). Composites of PLA–PEG
with hydroxyapatite were also evaluated for articular car-
tilage repair in rabbits (Tamai et al., 2005) and in a
rabbit radii model (Kaito et al., 2005), showing enhanced
tissue repair in the animals treated with rhBMP-2 and
hydroxyapatite composites.
Poly(lactic-co-glycolic acid) (PLGA) combines the
adsorptive stability of PLA with the mechanical strength
of polyglycolic acid (PGA) and has received particular
attention (Winet and Hollinger, 1993). Biodegradation
of the synthetic composite is achieved by varying the
proportion of each of the two component materials
(Miller et al., 1977; Grayson et al., 2004). PLGA as a
carrier for rhBMP-2 delivery was reported in alveolar cleft
repair in dogs (Mayer et al., 1996), in gelatine sponge
composites in a rabbit ulna model (Kokubo et al., 2003),
Table 1. Synthetic polymer-based matrices/scaffolds for drug delivery of BMPs for tissue-engineering applications
Polymer(s)/carrier/scaffold structure Formulation Biological model References
PLA Scaffolds Rabbit ulna (He et al., 2003)
Scaffolds In vitro differentiation of chondrocytes (Yang et al., 2006)
Scaffolds Rat ectopic bone formation (Chang et al., 2007)
PLA–collagen Membrane Rabbit ectopic bone formation (Tian et al., 2004)
PLA–collagen–HA Composites Radius defects in dogs (Hu et al., 2003)
Composites Mice ectopic bone formation (Zhang et al., 2005)
PLA–PEG–HA Composites Rabbit radius model (Kaito et al., 2005)
Composites Articular cartilage repair rabbits (Tamai et al., 2005)
PLA–DX–PEG Scaffolds Femoral canine model (Murakami et al., 2003)
Scaffolds Rat cranial defects (Suzuki et al., 2006)
Scaffolds Mice ectopic bone formation (Kato et al., 2006)
PLA–DX–PEG–CaP Composites Ectopic bone formation in mice (Matsushita et al., 2004)
Composites Spinal fusion in rabbits (Namikawa et al., 2005)
Composites Femur defects in rabbits (Yoneda et al., 2005)
Composites Femur defects in rabbits (Matsushita et al., 2006)
PGA Membrane Periodontal repair in dogs (Wikesjo et al., 2003)
Scaffolds In vitro cartilage formation (Blunk et al., 2003)
Scaffolds Cervical spinal fusion in goats (Lippman et al., 2004)
PLGA Scaffolds Alveolar cleft repair in dogs (Mayer et al., 1996)
Scaffolds Rabbit radius defects (Hu et al., 2005)
Scaffolds Alveolar ridge defects in rats (Shimazu et al., 2006)
Scaffolds Canine mandible defects (Jones et al., 2006)
Scaffolds Reconstruction of orbital floor defects in sheep (Zheng et al., 2006)
PLGA–heparin Composite Rat ectopic model (Jeon et al., 2007)
PLGA–gelatine Composites Rabbit ulna defects (Kokubo et al., 2003)
Composites Tooth defects in dogs (Kawamoto et al., 2003)
Composites Tibia defects in dogs (Kokubo et al., 2004)
PEG-based Hydrogels Rat cranial defects (Lutolf et al., 2003a, 2003b)
PEG-based, heparin Hydrogels Rat critical-sized calvarial defects (Pratt et al., 2004)
PEG-based Hydrogels Rat critical-sized calvarial defects (Rizzi et al., 2006)
Polypropylene fumarate Hydrogels Proliferation of chondrocytes (Fisher et al., 2004)
Isopropylacrylamide Hydrogels Ectopic bone formation (Gao and Uludag, 2001)
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in tooth defects of dogs (Kawamoto et al., 2003) and in
combination with bone marrow cells in a rabbit segmental
bone defect model (Hu et al., 2005). These studies confirm
the good results that are usually obtained with PLGA
scaffolds; bone formation was observed successfully when
the scaffolds delivered rhBMP, as compared to controls.
The dosage of rhBMP was also observed to significantly
affect the repair of bone defects. Recently, PLGA scaffolds
have been also tested in rats (Shimazu et al., 2006),
a canine model (Jones et al., 2006) and sheep (Zheng
et al., 2006), showing that delivered BMP induced much
higher bone formation than the scaffold alone over the
several weeks following implantation. Another report,
which involved a PLGA scaffold conjugated to heparin,
showed that a much longer sustained release of rhBMP-
2 and significantly increased in vivo new formation of
bone were achieved (Jeon et al., 2007), indicating the
promising potential that heparin has as a stabilizing agent
for BMP bioactivity.
Synthetic polymers have been also formulated as
hydrogels for the delivery of BMPs. Since hydrogels
contain large amounts of water, they are interesting
devices for the delivery of therapeutic proteins. Lutolf
et al. (2003a, 2003b) reported using synthetic PEG-
based hydrogels that mimic the invasive characteristics of
extracellular matrices, with integrin-binding sites for cell
attachment and substrates for matrix metalloproteinases,
in a rat model for rhBMP-2 delivery. The authors
demonstrated that cells were able to fully penetrate the
hydrogels and bone tissue was formed within 3–4 weeks
in the gels that delivered rhBMP-2. Similarly, PEG-
based hydrogels were reported by Pratt et al. (2004),
showing that cells were able to fully invade the gel
networks that were conjugated with peptides that
mimic characteristics from extracellular matrix, such
as plasmin and a heparin molecule to improve the
rhBMP-2 stability. In another study, Fisher et al. (2004)
evaluated thermoreversible hydrogels of poly(propylene
fumarate–co-ethylene glycol) that mimicked properties of
cartilage matrix hydrophilic proteoglycans, for cartilage
tissue engineering, using rhBMP-7. The solutions of this
polymer were aqueous at 25 ◦C but readily polymerized
into gel above 35 ◦C. The group proposed the use of these
hydrogels for articular cartilage repair. Identically, Gao
and Uludag (2001) also reported using rhBMP-2 in N-
isopropylacrylamide-based thermoreversible hydrogels in
a rat model. The authors studied the effect of different
hydrogel compositions on the in vivo retention of rhBMP
and conclude that these polymers were very versatile
for delivering proteins such as BMPs in more effective
and controlled ways. A major disadvantage of the use
of synthetic polymers is the risk of an inflammatory
response, due to acidic by-products of degradation (Winet
and Hollinger, 1993), which may be also detrimental
to the stability of the incorporated BMPs. This has led
researchers to look forward to other materials, such as
collagen and other natural polymers, as alternatives for
BMP delivery.
3.2. Collagen
Collagen is the major non-mineral component of bone
and also the most abundant protein in connective tissues
of mammals. Collagen has received much attention
due to having good biocompatibility, degrading into
physiologically compatible products and being suitable
for interaction with cells and other macromolecules. The
large variety of collagen formulations includes collagen
gels, demineralized bone matrix, fibril collagen, collagen
strips, membranes, absorbable collagen sponges and
composites (Kirker-Head, 2000; Geiger et al., 2003).
Another advantage is that collagen can be processed in
aqueous form. Collagen also has a favourable influence
on cell infiltration and wound healing. During the last
years, most researchers have focused on the use of
absorbable collagen sponges, although several other
formulations have been investigated (Kirker-Head, 2000).
Collagen sponges are very versatile, easily manipulated
and wettable. The manufacture of collagen sponge carrier
depends on several factors, including sponge mass, cross-
linking methods, sterilization methods, soaking time,
protein concentration and buffer composition (Geiger
et al., 2003). These steps impact the interaction of the
BMP with the collagen carrier and therefore the profile
and the efficacy of released protein. For collagen sponges,
binding of rhBMP is highly dependent on pH. Studies
using modified versions of recombinant BMP led to the
conclusion that modification of the isoelectric point could
bring up to 100-fold differences in the retention of protein
to the collagen carrier (Uludag et al., 1999b). Binding
of rhBMP-2 is therefore dependent on the isoelectric
point of the two proteins and other factors, such as
ionic strength. Collagen sponges have since been tested
and evaluated in several animal models and clinical
trials for cases of fracture repair, critical size defects,
spinal fusion and dental and craniofacial reconstruction
(Geiger et al., 2003). The collagen sponge consists of
lyophilized rhBMP, which is reconstituted with water
prior to injection and impregnates the collagen sponge
for several minutes before implantation. Two models
using collagen sponges delivering recombinant human
BMP-2 or BMP-7 were approved by the FDA for human
use as an alternative to bone grafts, for spinal fusion
and long bone fractures, after many pre-clinical trials
that have been recently reviewed (Gautschi et al., 2007).
The collagen sponge holds the BMP and releases it
only in the local environment where the surgery was
performed, eliminating the need to harvest autologous
bone, which causes post-operative pain. Based on the
extensive preclinical and clinical trials, the use of collagen
sponges delivering BMPs has been revealed to be a safer
and superior alternative to autogenous bone grafting.
However, although showing success, collagen sponges
pose risks of immunogenic reactions, since the collagen
used on these applications is derived from animal tissues,
creating concerns about the risks of transmission of
infectious agents and immunological reactions. For this
reason, the development of a superior carrier material
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Table 2. Natural origin polymer-based matrices for delivery of BMPs for tissue-engineering applications. Please refer to Table 3 for
micro- and nanoparticle formulations
Polymer(s)/carrier Formulation Biological model References
Alginate Hydrogels Ectopic bone formation in mice (Simmons et al., 2004)
Gels, synthetic BMP-2 oligopeptides Ectopic bone formation and tibial
defects in rats
(Suzuki et al., 2000; Saito et al.,
2003a, 2004, 2005a)
Gels Rabbit radial bone defects (Saito et al., 2006)
Carboxymethylchitosan – In vivo cartilage formation (Mattioli-Belmonte et al., 1999)
Chitosan Nanofibre membranes Differentiation of osteoblast cells (Park et al., 2006)
Chitosan films Differentiation of C2C12 cell line (Lopez-Lacomba et al., 2006)
Chitosan–alginate Gels Trabecular bone formation in mice (Park et al., 2005a)
Chitosan–gelatine Composites Differentiation of
osteoblasts/myoblasts
(Liang et al., 2005)
Chitosan–PGA Composites ∗ (Hsieh et al., 2006)
Dextran Hydrogels Rat ectopic model (Maire et al., 2005)
Fibrin Sealant Dental pulp of dogs (Ren et al., 2000)
Gels Rats, rabbits, dogs and cats;
different types of bone defects
(Schmoekel et al., 2004, 2005a,
2005b)
Sealant Rat calvarial defects (Han et al., 2005)
Sealant in PCL scaffolds ∗ (Rai et al., 2005)
Sealant Ectopic bone formation in mice (Zhu et al., 2006a, 2006b)
– Humans, frontal bone defect (Arnander et al., 2006)
Sealant Differentiation of rabbit bone
marrow cells
(Cui et al., 2007)
Fibrin–CaP Sealant Rat calvarial defects (Hong et al., 2006)
Fibrin–collagen Sealant in collagen sponge Rat spinal model (Patel et al., 2006)
Gelatine Hydrogels Rabbit skull defects (Hong et al., 1998)
Hydrogels Ectopic bone formation in mice (Yamamoto et al., 2001, 2003)
Hydrogels Critical-sized defects in rabbit ulnas (Yamamoto et al., 2006)
Hydrogels Skull; non-human primates (Takahashi et al., 2007)
Gelatine/dextran Hydrogels Differentiation on human
periodontal ligament cells
(Chen et al., 2007a, 2007b)
Hyaluronic acid Hydrogels Ectopic bone formation in rats (Bulpitt and Aeschlimann, 1999)
Sponges Alveolar ridge defects in dogs (Hunt et al., 2001)
Scaffolds Differentiation of CH3H10T1/2 cells (Kim and Valentini, 2002)
– Periodontal repair in dogs (Wikesjo et al., 2003)
Gels Osteotomy in non-human primates (Seeherman et al., 2004)
Gels Non-union tibial defects in rabbits (Eckardt et al., 2005)
Sponges Rat mandibular defects (Arosarena and Collins, 2005a,
2005b)
Hyaluronan acrylated Hydrogels Rat calvarial defects (Kim et al., 2007)
Hyaluronic acid–Ti Composites Cranial defects in rats (Itoh et al., 2001)
Hyaluronic acid–HA Scaffolds Osteointegration in cancellous bone
in sheep
(Aebli et al., 2005)
Hyaluronic acid–PLA Composites Critical size defect in rat femurs (Vogelin et al., 2005)
Silk fibroin Films Cranial defects in mice (Karageorgiou et al., 2004)
Scaffolds, loaded with human stem cells Cranial defects in mice (Karageorgiou et al., 2006)
Electrospun nanofibres Differentiation of human bone
marrow cells
(Li et al., 2006)
Scaffolds, loaded with human stem cells Critical size femur defects in rats (Kirker-Head et al., 2007)
∗These studies involved solely material testing and delivery kinetics, with no in vitro or in vivo bioactivity models
for BMP delivery based on other natural polymers is
currently being investigated. Alternatively, other sources
of collagen, i.e. of recombinant origin, provides a means
of obtaining reliable and chemically defined sources
of purified human collagens that are free of animal
components (Yang et al., 2004).
3.3. Natural origin polymers
The materials for tissue engineering applications should
ideally mimic the natural environment of tissues and, in
this regard, natural polymers can send signals to guide
cells at the various stages of their development and thus
accelerate healing (Mano and Reis, 2007). There are
several natural polymers that may be used as carriers
for BMP delivery (See Table 2). These include collagen,
starch-based polymers, chitin and chitosan, hyaluronans,
alginate, silk, agarose, soy- and alga-derived materials,
and poly(hydroxyalkanoates) (Mano et al., 2007). Several
of these polymers are derived from substances occurring in
bone, cartilage or the extracellular matrix. For this reason,
these materials often present excellent properties for
use in regenerative medicine applications, such as being
biodegradable, bioresorbable and versatile, as they may
be processed into different formulations (Malafaya et al.,
2003; Gomes et al., 2004). Natural polymers may present
risks of immunogenic reactions and disease transmission,
and disadvantages such as the sourcing and processing
of the materials. Nevertheless, researchers have been
looking for materials from plant origin and produced
by microorganisms and/or from recombinant technology
which may overcome these concerns.
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Alginate is a generally safe polysaccharide, known to
support the proliferation of chondrocytes in vitro (Park
et al., 2005b). Very interesting work has been developed
by Saito and colleagues with small synthetic peptides
corresponding to BMP-2 regions binding to cell receptors,
incorporated in cross-linked alginate gels, showing in vitro
osteogenic differentiation and success in repairing bone
defects in rats (Saito et al., 2003a, 2004, 2005a) and
in rabbit radial bone defects (Saito et al., 2006). The
use of alginate seems to be particularly appealing for
cartilage tissue-engineering applications, since alginate is
a major component of cartilage tissue. Alginate hydrogels
were also reported for the delivery of rhBMP-2 in rats
(Simmons et al., 2004) with the use of bone marrow cells
with RGD peptide for improving cell adhesion.
Chitosan is another natural degradable polymer,
obtained by alkaline deacetylation of chitin, extracted
from the exoskeletons of arthoropods. Chitosan has
been formulated in many forms, such as hydrogels
(Baran et al., 2004) and fibre meshes (Tuzlakoglu et al.,
2004), that showed potential for use in osteochondral
tissue engineering, making it suitable for BMP delivery
(Prabaharan and Mano, 2005). Several studies have
reported the use of chitosan for delivering BMPs,
particularly in composites with synthetic polymers or with
other natural polymers. A chitosan–alginate composite
gel, loaded with mesenchymal stem cells and rhBMP-
2, was evaluated as an injectable tissue-engineering
construct in mice and induced new trabecular bone
formation over a period of 12 weeks (Park et al., 2005a).
Liang and colleagues described a chitosan–gelatine
scaffold with incorporated rhBMP-2 (Liang et al., 2005)
which demonstrated increased expression of bone-marker
osteocalcin in osteoblast and myoblast cell lines. In
another report, a chitosan blend with PGA was studied
as a novel delivery carrier for rhBMP-2 (Hsieh et al.,
2006). Derivatives of chitosan are also reported. Chemical
modification of chitosan may enhance certain bioactive
properties and increase its solubility in water, thus aiding
in the incorporation of rhBMPs, such as in the case of
carboxymethyl chitosan. Mattioli-Belmonte et al. (1999)
reported the use of N,N-dicarboxymethyl chitosan, with
delivery of rhBMP, for enhancing cell proliferation and
healing in articular cartilage lesions. Recently, rhBMP-2
was immobilized directly on a guided bone-regenerative
membrane surface, made of chitosan nanofibres, that
functioned as a bioactive surface to enhance bone-healing
(Park et al., 2006). The BMP-2-conjugated membrane
surface retained bioactivity for up to 4 weeks of
incubation, as well as holding over 50% of the initial
BMP-2 attached, promoting cell attachment, proliferation,
ALP activity and calcification, when compared with
BMP-2 absorbed to the membrane. In two other
studies, dextran/gelatine-based microspheres, containing
rhBMP-2, were adhered to chitosan films for guided-
tissue regeneration (Chen et al., 2005a) and chitosan
membranes activated with BMP-2 were also reported
to successfully differentiate C2C12 cells (Lopez-Lacomba
et al., 2006).
Fibrin is derived from blood cots and can be formulated
into an adhesive glue-like delivery system (Hattori, 1990).
Fibrin has been used as a delivery system for BMPs
in a variety of animal models, including the use of a
fibrin–fibronectin sealing system for rat calvarial defects
as a carrier for rhBMP-4 (Han et al., 2005) and for rhBMP-
2 (Hong et al., 2006), and a fibrin sealant with rhBMP-2
in the healing of dental pulp of dogs (Ren et al., 2000). In
these reports, bone formation was much higher when the
fibrin carrier was loaded with the rhBMP, as compared
to controls. Fibrin glue might be also a great aid in
limiting the diffusion of BMPs into the surrounding tissues,
which could cause undesirable biological effects. In a rat
spinal model, fibrin glue significantly limited the diffusion
of rhBMP-2 that was loaded into a collagen sponge,
preventing the BMP from inducing bone growth in the
surrounding spinal cord and nerves (Patel et al., 2006).
Interesting research has been developed by the Hubbell
group with the use of fibrin matrices for the delivery
of rhBMPs (Schmoekel et al., 2004, 2005a, 2005b). The
group studied the influence of a non-glycosylated form
of rhBMP-2 (Schmoekel et al., 2004) in fibrin. Since non-
glycosylated rhBMP-2 is less soluble, retention into the
fibrin scaffold was enhanced. The fibrin matrices were
used to treat critical-size defects and non-unions in rats,
dogs and cats. In these studies, bridging of bone defects
showed more successful percentages of tissue healing
when compared to controls. The group has also reported
the use of a fusion BMP protein with an affinity domain
to fibrin to increase binding to the carrier (Schmoekel
et al., 2005b). Recently, a study using fibrin constructs
to deliver rhBMP-2, vascular endothelial growth factor
(VEGF) and fibroblast growth factor-2 (FGF-2), combined
with hyaluronic acid or collagen, dramatically improved
the ability of blood vessels to directly invade the fibrin-
based scaffolds (Smith et al., 2007). Finally, a human
trial was reported showing partial reconstruction of a
frontal bone defect using heparin together with bovine
collagen, hyaluronic acid and fibrin as vehicles for rhBMP-
2 (Arnander et al., 2006). Altogether, fibrin glue certainly
seems to be a very useful addition to a bone tissue-
engineering scaffold using BMPs, considering that it aids
in promoting osteoinduction (Schwarz et al., 1993) and
retention of growth factors (Hubbell, 2006).
Hyaluronans are present in the extracellular matrix
and can be formulated into gels, sponges and pads.
Hyaluronans have been used in a variety of trials as a
delivery vehicle for rhBMPs, including in sponge form in
the treatment of alveolar ridge defects in dogs (Hunt et al.,
2001), periodontal repair in dogs (Wikesjo et al., 2003),
tibial defects of rabbits (Eckardt et al., 2005), in sheep
in combination with hydroxyapatite (Aebli et al., 2005),
in the healing of critical size defect in rats in composites
with polylactic acid (Vogelin et al., 2005), and in gel and
paste forms in non-human primates (Seeherman et al.,
2004). Kim and Valentini (2002) evaluated the kinetics
of hyaluronic acid as a delivery system for rhBMP-2
in vitro and demonstrated that hyaluronan-based carriers
retained more BMP than collagen gels. In two other
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studies, hyaluronic acid was used to deliver BMPS for
treating mandibular defecs of rats (Arosarena and Collins,
2005a, 2005b). Significantly more bone was formed in
presence of rhBMP-2 and, although not significant, the
volumes of new bone were larger for the hyaluronic acid
carrier. Recently, a acrylated hyaluronic acid hydrogel
was used with human mesenchymal stem cells and
rhBMP-2 for healing of rat calvarial defects (Kim et al.,
2007). Higher levels of osteocalcin expression and bone
formation occurred when the BMP-2 and stem cells were
tested. Diverse hydrogel formulations of hyaluronic acid
were also evaluated by Bulppit and Aeschlimann (1999),
showing excellent cell infiltration and osteochondral
differentiation when loaded with BMP-2 in combination
with either insulin growth factor-1 or transforming growth
factor beta, implanted into rats. Hyaluronans are observed
to interfere positively with BMP cascade (Zou et al., 2004)
and, since these are part of the extracellular matrix, they
may well be priority choices as scaffolds for the delivery
of BMPs in regenerative medicine of bone.
Gelatine has been used mostly in form of hydrogels for
delivery of BMPs. Gelatine is an irreversibly hydrolysed
form derived from collagen that is usually cross-linked or
hardened through thermal treatment to reduce its high
water solubility and enhance the retention of protein to
achieve a long-term release. Gelatine hydrogels delivering
rhBMP-2 were studied in rabbit skulls (Hong et al., 1998),
in mice (Yamamoto et al., 2003) and recently in the skulls
of non-human primates (Takahashi et al., 2007). Gelatine
hydrogels delivering rhBMP-2 were observed to show
higher levels of ALP and osteocalcin in comparison with
rhBMP-2 delivered in collagen sponges (Yamamoto et al.,
2003). Recently, thermomechanical hydrogels based on
methacrylated dextran in combination with gelatine have
been reported by Chen et al. (2007a, 2007b). The group
used rhBMP-2 encapsulated in microspheres of the same
materials, loaded into the hydrogels, which delivered the
growth factor over a period of 18–28 days. Their work is
discussed below in the section on nanoparticles.
Dextran is another natural polysaccharide, synthesized
by some bacteria, that has attracted attention for use
as a BMP delivery system, because of its excellent
hydrophilic nature and biocompatibility. Dextran has
been particularly used in the form of nanospheres for
delivery of rhBMPs, which is detailed in a later section.
Dextran hydrogels has been evaluated for rhBMP-2
delivery, both in vitro and in vivo, in a rat ectopic model,
showing formation of new bone (Maire et al., 2005).
The possibility of using natural polymers for designing
intelligent hydrogel systems for BMP delivery is also an
interesting and very attractive option. However, no studies
have been reported with the use of these systems.
Starch-based polymers are another interesting alterna-
tive for delivering BMPs that was proposed by Reis as
materials with high potential for tissue engineering of
bone and cartilage, due to their interesting mechanical
properties (Malafaya et al., 2001; Elvira et al., 2002).
These starch-based polymers are used in composites with
different synthetic polymers and have been formulated
into a variety of forms, such as hydrogels (Pereira et al.,
1998), nanofibres (Tuzlakoglu et al., 2005), microparti-
cles (Silva et al., 2004) or 3D scaffolds (Gomes et al.,
2002). The wide variety of formulations and composites
make these polymers suitable scaffolds for bone tissue
engineering and controlled release of BMPs. In general,
composites of natural polymers with synthetic polymers
may become the future option of choice for bone tissue
engineering, since they combine the specificities of syn-
thetic and natural polymers to produce superior materials.
Silk fibroin is a protein derived from cocoons made
by the larvae of silkworms. Silk has been proposed and
widely investigated as a delivery carrier for BMPs in some
contributions reported by the Kaplan group. In one study,
rhBMP-2 was directly immobilized on silk fibroin films
and the effect of the delivery system studied in human
bone marrow stromal cells and in critical-sized cranial
defects in mice (Karageorgiou et al., 2004). The rhBMP
retained its biological activity. In another report, silk
scaffold fibres, prepared by electrospinning, were used
to deliver rhBMP-2 and hydroxyapatite nanoparticles for
in vitro bone formation (Li et al., 2006). The rhBMP-2
survived the aqueous-based electrospinning process in
bioactive form and induced osteogenesis in cultures of
human mesenchymal stem cells. The group also tested
BMP-2 delivered via silk fibroin scaffolds in critical size
defects in mice (Karageorgiou et al., 2006). In both
studies, the delivered rhBMP-2 increased levels of ALP
activity and calcium deposition and transcript levels for
bone sialoprotein, osteopontin, osteocalcin and runx2. In
recent years Meinel and co-workers have evaluated the
use of silk for tissue engineering constructs with silk–RGD
covalently bound matrices, in human mesenchymal cells
(Meinel et al., 2004), but not with use of BMPs. Meinel
et al. (2006) tested human stem cells loaded in silk fibroin
scaffolds, in combination with rhBMP-2, and compared
stem cells transfected with BMP-2 via an adenovirus
with exogenous protein. The expression of osteogenic
markers was induced but the BMP was not studied
when delivered directly on the silk scaffolds. Recently,
rhBMP-2 delivered via silk fibroin scaffolds in combination
with human mesenchymal stem cells was reported, with
promising results, in the healing of critical-sized defects
of femurs in rats (Kirker-Head et al., 2007). Compared
with other protein-based materials, such as collagen, silks
have distinguishable mechanical properties, presenting
slower degradation times and thus allowing adequate
time for proper bone remodelling. For this reason,
silk is a feasible and potential option as a carrier for
the controlled delivery of BMPs and, in general, for
generating diverse bone tissue-engineering constructs for
clinical applications (Meinel et al., 2005). Other possible
sources of natural polymers for BMP delivery include
soy, casein, polyhydroxyalkanoate, polyhydroxybutyrate,
corals, carrageenan, gellan gum, agarose and other fibrous
proteins, such as keratin and elastin (Kirker-Head et al.,
2007).
Copyright  2008 John Wiley & Sons, Ltd. J Tissue Eng Regen Med 2008; 2: 81–96.
DOI: 10.1002/term
88 P. C. Bessa et al.
3.4. Ceramics
Many studies have been dedicated to the understanding of
the processes of bone mineralization and it was concluded
that ceramic materials, such as hydroxyapatite (HA) and
other types of calcium phosphates, can, when implanted,
promote the formation of a bone-like mineral surface layer
that leads to an increased interface between the materials
and the surrounding bone. Calcium phosphate for tissue
engineering of bone includes the use of calcium phosphate
layers, films or coatings to promote bone ingrowth, and
the use of calcium phosphate fillers to replace fractured
or damaged bone. Hydroxyapatite (HA) is a form of
calcium phosphate mineral that comprises 70% of bone
and can be formulated as a powder, granules, disks or
blocks (Tsuruga et al., 1997). However, for bone tissue-
engineering applications, specific formulations work
better than others, dependent on the geometric structure
of the carrier (Kuboki et al., 1998). Hydroxyapatite is a
fairly osteoconductive material, and has been used for
BMP delivery alone (Noshi et al., 2001) or in composites
with natural or with synthetic polymers, as previously
detailed. Hydroxyapatite has been used in combination
with collagen for rabbit spinal fusion (Kraiwattanapong
et al., 2005), with natural origin polymers (Aebli et al.,
2005), with tricalcium phosphate in a rabbit calvarial
model delivering rhBMP-2 (Schopper et al., 2007),
for differentiating mesenchymal stem cells with BMP-
14/GDF-5 (Shimaoka et al., 2004), or for lumbar spinal
fusion in non-human primates (Boden et al., 1999). Based
on these and other studies, hydroxyapatite has proved to
be a suitable carrier for BMP delivery, not only enhancing
the delivery of the growth factor but also in aiding its
retention to the carrier and the osteoconductivity of the
scaffold (Uludag et al., 1999a).
Calcium phosphates for delivery of BMPs include
calcium phosphate (Ca-P) cements and ceramics and
calcium phosphate coatings. Ca-P cements have been
extensively investigated, as they are osteoconductive,
biocompatible and show fast deposition of new bone
at the cement surface (Driessens et al., 1998). The
BMP may be incorporated into low-temperature Ca-
P cements by adding the protein in lyophilized form,
or in aqueous phase prior to formation of cement,
without any risk of denaturation of the growth factor.
In high-temperature cements, the BMP is generally only
adsorbed onto the surface. A porous structure can be
fabricated to mimic the structure of trabecular bone
(Dutta Roy et al., 2003). Trials for rhBMP-2 delivery
have included studies in rabbit ulnas (He et al., 2003)
and femurs (Cao et al., 2006) and a canine tibial
defect model (Edwards et al., 2004). These studies have
demonstrated that the use of Ca-P cements accelerates
bone healing. Trials are have also demonstrated the
efficacy of calcium phosphate matrices in some non-
human primates trials, such as in alveolar ridge surgery
using a composite of Ca-P, hydroxyapatite and a collagen
sponge (Miranda et al., 2005), in osteotomy sites with
a single percutaneous injection of rhBMP-2 loaded
into Ca-P cements (Seeherman et al., 2006a), and in
posterolateral fusion, where Ca-P functioned as a bulking
agent to improve the osteogenic potential of rhBMP-2
loaded onto an absorbable collagen sponge (Barnes et al.,
2005). Seeherman et al. (2006b) also reported achieving
bridging of critical-sized defects in rabbits using the same
minimally invasive injectable Ca-P cements. Ruhe´ et al.
(2005, 2006) also reported several in vivo studies with the
use of calcium phosphate cements loaded with rhBMP-
2. A main advantage of the use of calcium phosphates
compared to other carriers is that, in general, high doses
of rhBMPs are not required (Yuan et al., 2001).
Calcium phosphate coatings are another elegant
approach for delivering BMPs, by incorporating these
growth factors into the lattice-work of these mineral
layers that may be used to coat specific scaffold
materials. The BMP is biomimetically deposited during
the formation of the calcium phosphate film that is
formed when the material is immersed in a solution
of simulated body fluid that mimics the human blood
plasma (Liu et al., 2004). The de Groot group has used
calcium phosphate-coated titanium disks for delivery
of rhBMP-2 in a rat model, showing that much lower
concentrations of BMP are required in comparison with
collagen matrices (Liu et al., 2004, 2005). Alternatively,
bioactive glass (45S5 – Bioglass), a synthetic surface
reactive glass that is commonly used as a filler for
damaged or fractured bone, may be also used to form
biomimetic calcium phosphate-coated scaffolds (Leonor
et al., 2003). The biomimetic layers, similar to bone
apatite, may be used in combination with BMPs to guide
the attachment and differentiation of bone precursor cells,
given that the coatings have been shown to promote
osteointegration and osteoinduction. Silva et al. (2004)
proposed using blends of starch with polylactic acid
and bioglass microspheres for the delivery of BMPs.
Promising potential arises from the fact that bioglass
is osteoconductive and osteoinductive, stimulating the
recruitment and differentiation of osteoblasts, which
produce new bone and completely resorb the material.
3.5. Microparticles and nanoparticles for BMP
delivery
The search for efficient, simple and cheap delivery systems
for drug targeting has led to great investment in the area of
nanoparticles and microparticles for drug delivery. Most
common materials for the design of nanodevices to deliver
BMPs include synthetic materials, natural polymers and
hydroxyapatite-based particles. Both nano-scale (up to
100 nm) and microspheres are reported (See Table 3).
Polylactic acid and polylactic-co-glycolic acid have
been used as materials for nanoparticle-based delivery
systems for BMPs. PLA was initially studied as a
carrier for BMPs in a rat ectopic bone formation model
(Saitoh et al., 1994), showing formation of new bone
at 4 weeks after implantation and mature bone after
24 weeks. However, by blending PLA with polyglycolic
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Table 3. Micro and nanoscale drug delivery systems based on synthetic and natural-origin polymers. The average size or size range
of the particles is noted on the formulation
Carrier Formulation/size Biological models References
PLGA Microparticles Rat calvarial bone defects (Kenley et al., 1994)
Microparticles (247–430 µm) Rat femurs (Lee et al., 1994)
Microparticles In vitro differentiation of osteoblasts (Oldham et al., 2000)
Microparticles Rabbit calvarial bone defects (Schrier et al., 2001)
Microparticles Sheep vertebrae (Phillips et al., 2006)
Nanoparticles (300 nm) Rat ectopic model (Wei et al., 2007)
PLGA/Ca-P Microparticles (66 µm) Rat ectopic model/cranial model (Ruhe et al., 2005)
PLA Microparticles Rat ectopic bone formation (Saitoh et al., 1994)
Collagen–HA Microparticles Rabbit femoral bone defects (Wang et al., 2003)
Nanocrystals/fibres Dogs, spinal fusion/tibial fractures (Itoh et al., 2004)
Chitosan–alginate Microparticles In vitro differentiation of rabbit bone marrow stem cells (Qin et al., 2003)
Dextran Nanoparticles (20 nm) In vitro differentiation of rabbit bone marrow stem cells (Chen et al., 2005b)
Dextran–PEG Microparticles (20–40 µm) In vitro differentiation of human periodontal ligament cells (Chen et al., 2006)
Dextran–gelatine Microparticles (20–40 µm) Canine defects (Chen et al., 2005a)
Microparticles (0.5–1.5 µm) Periodontal regeneration in dogs (Chen et al., 2007b)
acid in copolymer polylactic-co-glycolic acid (PLGA),
biodegradation is controlled by changing the proportions
of each of the two materials, since PLA degrades much
more slowly than PGA. Microspheres of PLGA have since
then been evaluated in diverse animal models, such as
in rat calvarial bone defects (Kenley et al., 1994), rat
femurs (Lee et al., 1994) and in calvarial defects in rabbits
(Schrier et al., 2001), forming much more bone when
BMPs were delivered via the PLGA particles. Interesting
work has been developed by Ruhe´ and colleagues, using
microspheres of PLGA in combination with Ca-P cement,
as carriers for rhBMP-2 delivery (Ruhe et al., 2005). The
release of rhBMP-2 was observed to be dependent on
composite composition and nanostructure, as well as on
the pH of the release medium. Sustained slow release
was observed, possibly due to the interaction of rhBMP-2
with the calcium phosphate cement. Delivery of rhBMP-
7 was evaluated in PLGA nanospheres encapsulated in
PLA scaffolds, with interconnected macroporous and
nano-fibrous architectures (Wei et al., 2007). The group
concluded that the carrier delivered rhBMP-7 in a
time-controlled manner and induced significant bone
formation.
Diverse natural origin materials were also proposed as
carriers at a nano- and micro-scale for delivering BMPs.
Collagen–hydroxyapatite microspheres were evaluated
for rhBMP-4 delivery in femoral defects of rabbits (Wang
et al., 2003). Regeneration occurred in the animal group
treated with BMP-4 particles, while with the carrier
alone the defects were filled with fibrous tissue and
inflammatory cells. Microspheres based on blends of
chitosan with sodium alginate were reported in vitro
in bone marrow-derived cells, showing an increased
in the levels of ALP (Qin et al., 2003). During recent
years, dextran-based microspheres and nanospheres were
extensively evaluated by Chen and colleagues for the
delivery of BMPs. In 2005, the group reported delivering
BMP-2 with dextran-based microparticles (20–40 µm) in
canine defects (Chen et al., 2005a) and nanoparticles
(20 nm) in the differentiation of rabbit bone marrow cells
(Chen et al., 2005b). One year later, the authors studied a
novel class of methacrylate dextran–PEG microspheres in
periodontal ligament cells (Chen et al., 2006). Recently,
the group reported dextran–gelatine microspheres loaded
into thermomechanical dextran/gelatine hydrogels to
deliver rhBMP-2 for periodontal regeneration in dogs
(Chen et al., 2007b). The group studied the kinetics of
release and demonstrated that, by changing the ratio of
components, the rhBMP release could be varied from 18
to more than 28 days (Chen et al., 2007a).
Nanoparticle technology seems definitely one of the
most promising approaches for the future of bone tissue
engineering, by overcoming some fundamental issues
in the methods applied for tissue regeneration such as
the insufficient mechanical strength of scaffolds and the
lack of stability or bioactivity of growth factors such as
BMPs at the defect site (Kim and Fisher, 2007). Major
nanotechnology areas of research, such as the fabrication
of scaffold–nanoparticle composites and the design of
nano-patterned materials, are some of the areas we found
with the greatest potential for the delivery of BMPs in
orthopaedic regenerative science.
4. Human clinics and the future of
bone tissue engineering
In the Western world, an estimated 5–10% of all bone
fractures show deficient healing, leading to delayed
union or non-union, causing significant morbidity and
psychological stress to the patients and bringing elevated
costs to society (Westerhuis et al., 2005). Fortunately,
the current advances in bone tissue engineering have led
researchers to find new strategies and devices with the
use of BMPs for accelerating the healing of bone tissues in
the orthopaedic field. In fact, by the end of 2007, nearly
1 million patients worldwide were projected to have been
treated with BMPs for diverse bone-related problems and
diseases (Pecina and Vukicevic, 2007). The clinical uses
of BMPs include spinal fusion, treatment of long bone
defects and non-unions, dental and periodontal tissue
engineering, craniofacial defects and diseases, fracture
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repair, the improvement of osteointegration with metallic
implants, musculoskeletal reconstructive surgery and
tendon and ligament reconstruction. There are currently
two main collagen-based products containing BMP-2 or
BMP-7 that were approved by the FDA in recent years for
human clinical use: Infuse Bone Graft (Medtronik, US;
Wyeth, UK), containing rhBMP-2, and Osigraft (Stryker
Biotech), containing rhBMP-7, known by the designation
of OP-1 (osteogenic protein-1). BMP-2 Infuse bone graft
was approved for certain interbody fusion procedures in
2002, for open tibial fractures in 2004, and for alveolar
ridge and sinus augmentations in 2007 (McKay et al.,
2007). BMP-7 Osigraft was approved for long bone
fractures and as an alternative to autografts in patients
requiring posterolateral lumbar spinal fusion. There has
been also an increasing number of trials that provide
supporting evidence for the use of rhBMP-7/OP-1 in the
treatment of open tibial fractures, distal tibial fractures,
tibial non-unions, scaphoid non-unions and atrophic long
bone non-unions (White et al., 2007).
4.1. Spinal fusion
Spinal fusion applications are an important part of
currently ongoing clinical trials (Carlisle and Fischgrund,
2005). Spinal fusions consist of nearly half of all grafting
surgery. Furthermore, failure rates of up to 35% have been
reported. The interest is in the use of rhBMPs to accelerate
healing in patients with disk degenerative disease,
removing the need for autograft harvesting and reducing
morbidity. Degenerative disc disease is defined as back
pain caused by degeneration of the discs, as confirmed
by clinical data and symptoms. The common approach is
to use a collagen or other carriers soaked with rhBMP
and place these within titanium spacers called cages
which are implanted into the spine. There are two types
of fusion approaches: posterolateral fusion, involving
placing the bone graft between the transverse processes in
the back of the spine, and interbody fusion, which involves
placing the bone graft between the vertebrae in the area
occupied by the intervertebral disk. In interbody fusion
of lumbar vertebrae, based in the success of previous
trials, a prospective study for rhBMP-2 was performed
by McKay and Sandhu (2002) involving 279 patients
with disk degenerative disease, from which 143 patients
received tapered lumbar cages filled with rhBMP-2 and
136 patients received the device filled with autologous
bone from iliac crest. Since, at the conclusion of the study,
higher rates of spinal fusion were observed for the rhBMP-
2 group and less operative time and morbidity were
reported, the FDA granted approval for the use of rhBMP-
2 in the treatment of single-level lumbar degenerative
disc disease. Posterolateral spinal fusions are common for
treating spondylolisthesis but require distinct mechanical
and biological properties of the carrier. Boden et al.
(2002), using rhBMP-2 delivered via a biphasic carrier
of tricalcium phosphate and hydroxyapatite, reported
achieving complete fusion in all patients treated with
rhBMP-2 as compared with the control group. Although
the carrier did not obtain approval from FDA, there are
several other trials currently ongoing in humans, such as
with collagen sponges (Glassman et al., 2007).
The efficacy of use of rhBMP-7/OP-1 as a replacement
for iliac crest autograft was first evaluated by Johnsson
et al. (2002), showing higher rates of fusion in postero-
lateral spinal fusions with application of rhBMP-7, which
were confirmed by further studies (Vaccaro et al., 2004;
Kanayama et al., 2006). With no adverse effects, OP-1
was considered a viable alternative to autograft and, as
a result, FDA gave approval of rhBMP-7 for patients who
have failed a posterolateral fusion and are at risk for
repeated pseudarthrosis. At present there is little focus
on human trials involving either the use of other BMPs
or the use of natural polymers as delivery carriers, but is
to be expected that these options will be soon evaluated
clinically, in the next few years, considering the current
state of biomaterials research.
4.2. Long bone fractures
In most cases where rhBMPs are applied to fractures,
these consist in non-unions of long bones. It is estimated
as an example that in the UK, 42% of these fractures are
of tibias, 20% are femurs and the rest are of other bones
(Giannoudis and Tzioupis, 2005). RhBMP-2 has received
FDA approval for use in treating open tibial fractures.
Initially, Govender et al. (2002) performed a randomized
trial with 450 patients having open tibial fractures. The
patients were randomized to receive different doses of
rhBMP-2, 0.75 mg/ml (total dose of 6 mg), 1.50 mg/ml
(total dose of 12 mg) or no rhBMP-2, in collagen sponges.
After 12 months, analysis showed accelerated healing and
reduced infection with increasing dosing of rhBMP-2.
There are numerous studies in the literature suggesting
that rhBMP-7/OP-1 is also a safe and effective alternative
for the treatment of diverse long-bone fractures and non-
unions. In tibial non-unions, a trial that led to multiple
regulatory approvals worldwide concluded that OP-1
delivered in a collagen sponge was a safe and effective
alternative to bone grafting (Friedlaender et al., 2001).
In scaphoid non-unions, Bilic et al. (2006) concluded that
OP-1 could allow successful use of allograft, eliminating
the donor site morbidity of an iliac crest autograft. In
another curious trial, McKee and colleagues assessed the
efficacy of OP-1 on treating diverse long bone non-unions
on 62 patients that failed previous autograft operations.
The bones involved included 16 tibiae, 18 clavicles, 11
humeri, 10 femora, four ulnae and three radii. At the
end of the study, 54 of 61 non-unions (89%) had healed,
indicating that rhBMP-7 was an effective treatment (White
et al., 2007).
4.3. Dental tissue engineering
In periodontal and dental tissue engineering, rhBMPs find
their place in inducing pulp stem cells to differentiate
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into odontoblasts and promoting the regeneration of pulp
and teeth. Since the pulp is an organ known to have
tremendous regenerative abilities, during recent years
tissue engineering has been considered as a promising
approach for diverse clinical cases, such as caries, pulpitis
and apical periodontitis (Nakashima and Akamine, 2005).
Particularly interesting is the fact that human pulp
stem cells have self-renewal ability and that tubular
dentine is formed after the transplantation of these
stem cells with hydroxyapatite power in mice (Gronthos
et al., 2002). Recombinant BMPs have been noted to
induce dentine formation in vivo when delivered with a
collagen scaffold (Nakashima, 1994). The ultimate goal
in dental tissue engineering using BMPs is in achieving a
complete restoration of the physiological, structural and
mechanical integrity of the native dentine–pulp complex,
including nerve and vascular regeneration (Nakashima
and Akamine, 2005).
4.4. Future challenges, a global perspective
Bone repair and regeneration with BMPs are ushering
in a new era in orthopaedics. The past 10 years have
seen practical demonstration of bone repair in a series
of animal studies and subsequently in clinical trials. The
expected value of BMPs in the treatment of bone defects,
spinal fusion applications and other types of related
applications is enormous. Extensive research in preclinical
models has led to the approval of restricted use for
human trials. However, despite the significant evidence
of potential for bone healing demonstrated in animal
models, future clinical investigations will be needed to
better define variables such as dose, scaffold and route of
administration. The impressive results of animal models
are difficult to replicate in humans. It is unclear why these
differences occur. Some insight is provided by the clear
species-specific dose response, ranging from 25 µg/ml in
rodents to 50 µg/ml in dogs, 100 µg/ml in non-human
primates and 800 µg/ml in humans (Luginbuehl et al.,
2004). The recruitment of bone precursor cells and bone
turnover may occur differently in rodents, small animals
and large mammals. Likewise, the dosing may not yet
be optimal. In fact, the concentrations of BMP in use are
supraphysiological and a million times higher (milligrams
in assays as compared to the nanogram range in vivo).
BMP inhibitors such as noggin or sclerotin, which are
upregulated by BMP presence, may be interfering and
providing a negative feedback effect on the bodily healing
mechanisms (Westerhuis et al., 2005). Understanding the
regulation between BMPs and BMP-inhibitors might be
a key issue. Moreover, different fractures may require
different dosages (Schmitt et al., 1999). Critical issues
to consider include the potential risk of BMPs inducing
heterotopic bone formation, especially when implanted
adjacent to neural tissues (Paramore et al., 1999), and
the serious issue of reported antibody formation, noted in
up to 38% of patients in some trials with BMPs (Walker
and Wright, 2002).
Clearly, the use of BMPs in orthopaedics is still in
its early days, but the latest trials in humans suggest
that an exciting and promising future will unfold in the
development of novel tissue-engineering products for a
wide range of clinical situations, with the use of BMPs. To
date, clinical trials have focused mostly on rhBMP-2 and
-7 and with the use of collagen as delivery materials.
However, given the intricate network of molecules
interplaying during bone regeneration, it is possible
that a ‘cocktail’ of different BMPs with simultaneous or
sequential release would be the most desirable approach
to clinical uses, instead of a single stimulus or molecule
(Hadjiargyrou et al., 2002). Raiche and Puleo (2004a,
2004b) have already explored the sequential release of
rhBMP-2 in combination with insulin-like growth factor-1
(IGF-1). However, the development of such a cocktail
for clinical cases may encounter difficulties, since the
commercial rights of the two currently approved rhBMPs
are for restricted use and owned by different companies
(Westerhuis et al., 2005). Nevertheless, in the near future,
the emergent advances with recombinant production of
BMPs (Klosch et al., 2005; Schmoekel et al., 2005b; Bessa
et al., 2007) will aid researchers in obtaining larger
amounts of bioactive rhBMPs which could be used for
tissue-engineering research and the development of novel
products.
With the excitement over the potential of other natural-
origin polymers as novel delivery systems for BMPs, there
is little doubt that these will also find relevant places
in regenerative medicine of bone and traumatology,
and may be soon approaching clinical trials in humans.
Diverse natural-origin polymers have shown promising
success for bone tissue engineering, such as fibrin,
hyaluronic acid, chitosan, silk fibroin and starch-based
composites. Furthermore, these overcome limitations and
disadvantages from the use of synthetic polymers and
the risks of disease transmission inherent to the use of
collagen from bovine sources. The recent advances in
biomaterials science will certainly boost the number of
tissue-engineering approaches for the healing of bone
with the use of BMPs. Novel strategies will possibly
involve the specific targeting of BMPs, in injectable
systems and stimulus-responsive hydrogels, the use of
nano-scale patterning or encapsulated particles, or with
the use of molecules combined with the BMP, mimicking
the extracellular matrix, all of which allow restricted and
site-specific delivery of these growth factors. Additionally,
the design of 3D specific-architecture scaffolds by methods
such as rapid prototyping or the design of bilayered
scaffolds surely ensures that the carrier for delivering
the BMP will closely mimic the bone structure. Guided
tissue-engineering delivery systems, which would deliver
not only BMPs but also angiogenic factors, would, for
instance, prompt the recruitment and distribution of
blood vessel precursor cells, which is necessary for the
formation of mature bone. Finally, the use of Ca-P
cements and biomimetic coatings is a very promising
approach, since it furthers mimics the bone mineral
make-up and aids in retaining the BMP and improving
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tissue–material integration. The expanding variety of
options for biomedical use of BMPs gives the promise that
the future of clinical regenerative medicine. and that of
BMPs, particularly for bone applications, will be certainly
be a bright one in the coming decades for millions of
people.
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